BioNTech's Cancer Candidate Clears Path for FDA Filing

A promising new cancer therapy from BioNTech has set the stage for a pivotal regulatory push in the United States. Detailed results from a Phase 2 study of the antibody-drug conjugate (ADC) candidate BNT323/DB-1303, also known as Trastuzumab Pamirtecan, were presented over the weekend, showing significant efficacy in a hard-to-treat form of advanced endometrial cancer. The data provide a crucial clinical foundation as the company accelerates its transformation into a fully-fledged oncology business.

The study focused on patients with HER2-expressing, recurrent endometrial carcinoma who had received prior systemic therapy. The candidate demonstrated an objective response rate of nearly 48% and a median progression-free survival of 8.1 months. BioNTech highlighted the therapy's manageable safety profile and consistent anti-tumor activity across all treated cohorts. These results are particularly notable as they come from the largest study to date for a targeted HER2-ADC in this specific cancer type.

This clinical success has immediate strategic implications. In partnership with DualityBio, BioNTech now plans to submit a marketing application to the U.S. Food and Drug Administration (FDA) as early as 2026. A confirmatory Phase 3 trial is already underway. The candidate is a cornerstone of a broader pipeline ambition: the company aims to have 15 Phase 3 programs in oncology active by the end of this year, part of its goal to build a comprehensive portfolio by 2030.

Should investors sell immediately? Or is it worth buying BioNTech?

This aggressive research drive comes at a cost, marking a definitive shift from the COVID-19 vaccine era. For the full year 2025, BioNTech reported a net loss of approximately €1.1 billion, fueled by high R&D spending and declining vaccine revenue. Despite this, its financial position remains robust, with cash, cash equivalents, and security investments totaling €17.2 billion at the end of 2025. The company has guided for 2026 revenues between €2.0 and €2.3 billion, weighted toward the second half of the year.

Investor attention now turns to a busy May schedule. The company will report first-quarter earnings on May 5, 2026, followed by its Annual General Meeting on May 15, 2026. Key resolutions at the virtual meeting will include the appropriation of retained earnings amounting to €6.9 billion, an expansion of the Supervisory Board from six to eight members, and the creation of new authorized capital of up to €129.5 million. The AGM is also expected to offer further details on the company's 2030 oncology strategy and the impending leadership transition.

That transition represents a profound change. Founders Ugur Sahin and Özlem Türeci are set to depart the management board by the end of 2026 to build a new mRNA-focused company, in which BioNTech will retain a minority stake. The upcoming board expansion, which aims to add clinical experts, is seen as a move to bolster governance for the company's next chapter.

Analysts are taking note of the clinical progress. Morgan Stanley recently reaffirmed its Overweight rating on BioNTech stock and slightly raised its price target to $126. The shares last traded at €79.40, leaving them down 3.76% for the year to date. The coming weeks will test how the market balances the near-term financial pressures of the strategic pivot against the long-term potential now being charted in its oncology labs.

Ad

BioNTech Stock: New Analysis - 12 April

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECHS | boerse | 69131272 |